Johnson & Johnson (NYSE:JNJ) Stock Price Down 2.5% – Here’s What Happened

Johnson & Johnson (NYSE:JNJ) traded down 2.5% on Wednesday . The stock traded as low as $246.05 and last traded at $247.5480. Approximately 10,002,910 shares were traded during mid-day trading, an increase of 19% from the average daily volume of 8,423,731 shares. The stock had previously closed at $253.85.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ beat Q2 expectations, posting adjusted EPS of $2.90 versus $2.85 expected and revenue of $25.31 billion versus $25.02 billion expected, showing continued strength in the core business.
• Positive Sentiment: The company raised full-year 2026 guidance, with EPS now forecast at $11.60-$11.75 and revenue at $100.8 billion-$101.4 billion, signaling management’s confidence in the outlook.
• Positive Sentiment: Pharmaceutical growth remains a key driver, especially Darzalex, Tremfya, and strong Spravato sales, which jumped 25% sequentially to $584 million and reinforce the long-term opportunity in depression treatment and related therapies. Article Title
• Neutral Sentiment: J&J also announced a quarterly dividend of $1.34 per share, which supports its appeal as a defensive income stock.
• Neutral Sentiment: Heavy call option activity suggests traders were positioning for a move around earnings, but the flow does not by itself explain the stock’s direction.
• Negative Sentiment: The stock is under pressure because the earnings beat was not viewed as dramatic enough to justify an immediate rerating, and investors may be taking profits after a strong run into the report.
• Negative Sentiment: Talc litigation and other legal risks continue to hang over the shares, limiting enthusiasm despite the improved outlook.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Bank of America raised their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Stifel Nicolaus increased their target price on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $283.00 to $284.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $261.26.

Johnson & Johnson Trading Down 2.5%

The company’s fifty day moving average is $238.18 and its two-hundred day moving average is $233.92. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market cap of $595.90 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.46 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.85 by $0.05. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.02 billion. During the same quarter in the previous year, the business posted $2.77 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts predict that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors have recently bought and sold shares of the business. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. United Bank boosted its stake in Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. grew its holdings in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. increased its position in shares of Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after purchasing an additional 6,584 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.